	medtronic mdt sees pct ings growth medtronic inc said it sees pct growth in sales and ings for the year ending april at an analysts meeting here the company said that for the year ending april it will  about mln dlrs or about dlrs a share on sales of about mln dlrs in the year ago period the company ed mln dlrs or dlrs a share on sales of mln dlrs winston wallin medtronic chairman said the company will improve market share in fiscal in cardiac pacemakers and expand its cardiovascular therapeutic product line wallin cautioned analysts not to quickly change their per share estimates for the company as he said medtronic will have heavy sales and marketing expenses in fiscal he said the company intends to reinvest its ings in its businesses and not in its dividends shareholders are better off if we grow the business rather than reinvest in dividends or share repurchases he said wallin said he sees medtronic s share of the total worldwide pacemaker market increasing to pct in fiscal from pct in fiscal he said the worldwide market for cardiovascualr therapeutic products which includes pacemakers valves catheters and lasers will be valued at about billion dlrs and will double that by wallin said our objective is to get a hold of new products and start building market share if we have to beg borrow or steal to get into new markets in the past medtronic s pacemakers have been plagued with a number of problems leading to product recalls regulators also have criticized the industry citing quality problems and a needless overprescription of pacemakers we have no knowledge of any major problems in our pacemakers or leads wallin said we intend to re establish our company as the quality leader in the industry glen nelson executive vice president for medtronics said the company intends to diversify internally and through acquisitions of companies in areas of medtronic s expertise such as drug delivery systems wallin said the pct ings growth for fiscal does not include dilutions from acquisitions we hope to have some safety provisions so that we won t have any major dilutions from an acquisition wallin also said the company will have virtual exclusivity in rate responsive pacemakers for all of fiscal the company markets activitrax the first single chamber pacemaker that varies heartrate in response to physical activity siemens ag a west german company is also developing a rate responsive pacemaker reuter 
